ATyr Roic vs Average Payables Analysis

ATYR Stock

3.35 0.10 2.90%

ATyr Pharma, financial indicator trend analysis is way more than just evaluating aTyr Pharma, prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether aTyr Pharma, is a good investment. Please check the relationship between ATyr Pharma, Roic and its Average Payables accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in aTyr Pharma,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

To learn how to invest in ATyr Stock, please use our How to Invest in ATyr Pharma, guide.

Roic vs Average Payables

Roic vs Average Payables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of aTyr Pharma, Roic account and Average Payables. At this time, the significance of the direction appears to have very week relationship.

The correlation between ATyr Pharma,'s Roic and Average Payables is 0.25. Overlapping area represents the amount of variation of Roic that can explain the historical movement of Average Payables in the same time period over historical financial statements of aTyr Pharma,, assuming nothing else is changed. The correlation between historical values of ATyr Pharma,'s Roic and Average Payables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Roic of aTyr Pharma, are associated (or correlated) with its Average Payables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Average Payables has no effect on the direction of Roic i.e., ATyr Pharma,'s Roic and Average Payables go up and down completely randomly.

Correlation Coefficient

0.25

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Roic

Return on Invested Capital, a profitability ratio that measures the return that an investment generates for those who have provided capital, such as debt holders and equity holders.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Most indicators from ATyr Pharma,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into aTyr Pharma, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in aTyr Pharma,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

To learn how to invest in ATyr Stock, please use our How to Invest in ATyr Pharma, guide.At this time, ATyr Pharma,'s Sales General And Administrative To Revenue is relatively stable compared to the past year. As of 04/27/2025, Enterprise Value is likely to grow to about 284.6 M, while Selling General Administrative is likely to drop slightly above 11.7 M.

	2024	2025 (projected)
Interest Expense	956.8K	567.6K
Depreciation And Amortization	1.5M	1.3M

Interest Expense Depreciation And Amortization

ATyr Pharma, fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Stockholder Equity	Short Term Investments	Short Long Term Debt	Net Receivables	Capital Lease Obligations
Total Assets		0.3	0.69	0.67	0.83	0.43	-0.65	-0.31	-0.65	0.8	0.44	0.67	0.02	0.98	0.48	-0.26	0.55	-0.17	0.99	-0.09	0.62	0.79	0.88	-0.18	0.15	0.49
Short Long Term Debt Total	0.3		0.37	0.7	0.12	0.39	-0.01	0.22	-0.42	0.41	0.15	0.08	0.17	0.32	0.29	0.07	0.11	0.16	0.32	0.51	0.44	0.39	0.28	-0.17	0.18	0.43
Other Current Liab	0.69	0.37		0.78	0.49	0.85	-0.75	0.01	-0.72	0.83	0.14	0.62	0.25	0.6	0.72	-0.08	0.5	0.02	0.65	-0.27	0.67	0.74	0.59	-0.26	0.46	0.91
Total Current Liabilities	0.67	0.7	0.78		0.45	0.67	-0.49	0.01	-0.72	0.78	0.26	0.61	0.28	0.6	0.57	-0.07	0.39	0.06	0.62	0.37	0.62	0.74	0.53	-0.26	0.31	0.71
Total Stockholder Equity	0.83	0.12	0.49	0.45		0.33	-0.43	-0.13	-0.6	0.6	0.18	0.55	-0.17	0.81	0.38	-0.75	0.49	-0.69	0.82	-0.11	0.54	0.78	0.81	-0.11	0.11	0.36
Property Plant And Equipment Net	0.43	0.39	0.85	0.67	0.33		-0.65	0.35	-0.77	0.61	-0.15	0.44	0.48	0.34	0.9	-0.12	0.62	-0.05	0.39	-0.2	0.79	0.64	0.45	-0.59	0.4	0.97
Current Deferred Revenue	-0.65	-0.01	-0.75	-0.49	-0.43	-0.65		0.03	0.79	-0.59	-0.07	-0.38	-0.37	-0.61	-0.71	0.0	-0.68	-0.06	-0.65	0.35	-0.62	-0.74	-0.64	0.42	-0.24	-0.64
Net Debt	-0.31	0.22	0.01	0.01	-0.13	0.35	0.03		-0.3	-0.3	-0.92	-0.48	0.3	-0.28	0.32	-0.18	0.2	-0.18	-0.25	0.13	0.2	0.13	0.11	-0.26	0.14	0.27
Retained Earnings	-0.65	-0.42	-0.72	-0.72	-0.6	-0.77	0.79	-0.3		-0.58	0.1	-0.29	-0.39	-0.63	-0.83	0.33	-0.76	0.24	-0.67	-0.05	-0.83	-0.94	-0.74	0.55	-0.19	-0.74
Accounts Payable	0.8	0.41	0.83	0.78	0.6	0.61	-0.59	-0.3	-0.58		0.47	0.82	0.32	0.7	0.6	-0.13	0.55	-0.03	0.72	-0.17	0.68	0.66	0.55	-0.31	0.27	0.7
Cash	0.44	0.15	0.14	0.26	0.18	-0.15	-0.07	-0.92	0.1	0.47		0.53	-0.16	0.42	-0.15	0.21	-0.08	0.25	0.38	0.05	0.04	0.02	0.01	0.09	-0.09	-0.08
Non Current Assets Total	0.67	0.08	0.62	0.61	0.55	0.44	-0.38	-0.48	-0.29	0.82	0.53		0.1	0.53	0.36	-0.18	0.3	-0.1	0.54	-0.11	0.41	0.4	0.34	-0.15	0.26	0.5
Non Currrent Assets Other	0.02	0.17	0.25	0.28	-0.17	0.48	-0.37	0.3	-0.39	0.32	-0.16	0.1		-0.02	0.69	0.27	0.71	0.3	0.01	-0.04	0.62	0.15	0.06	-0.84	-0.15	0.43
Cash And Short Term Investments	0.98	0.32	0.6	0.6	0.81	0.34	-0.61	-0.28	-0.63	0.7	0.42	0.53	-0.02		0.43	-0.24	0.53	-0.16	1.0	-0.05	0.59	0.77	0.91	-0.15	0.04	0.39
Common Stock Shares Outstanding	0.48	0.29	0.72	0.57	0.38	0.9	-0.71	0.32	-0.83	0.6	-0.15	0.36	0.69	0.43		-0.15	0.87	-0.08	0.47	-0.23	0.94	0.67	0.54	-0.81	0.08	0.86
Non Current Liabilities Total	-0.26	0.07	-0.08	-0.07	-0.75	-0.12	0.0	-0.18	0.33	-0.13	0.21	-0.18	0.27	-0.24	-0.15		-0.23	0.99	-0.25	0.03	-0.25	-0.45	-0.36	0.04	-0.04	-0.1
Other Current Assets	0.55	0.11	0.5	0.39	0.49	0.62	-0.68	0.2	-0.76	0.55	-0.08	0.3	0.71	0.53	0.87	-0.23		-0.2	0.56	-0.25	0.88	0.64	0.63	-0.84	-0.05	0.58
Total Liab	-0.17	0.16	0.02	0.06	-0.69	-0.05	-0.06	-0.18	0.24	-0.03	0.25	-0.1	0.3	-0.16	-0.08	0.99	-0.2		-0.17	0.08	-0.18	-0.35	-0.29	0.03	0.0	-0.02
Total Current Assets	0.99	0.32	0.65	0.62	0.82	0.39	-0.65	-0.25	-0.67	0.72	0.38	0.54	0.01	1.0	0.47	-0.25	0.56	-0.17		-0.08	0.61	0.8	0.92	-0.17	0.11	0.45
Short Term Debt	-0.09	0.51	-0.27	0.37	-0.11	-0.2	0.35	0.13	-0.05	-0.17	0.05	-0.11	-0.04	-0.05	-0.23	0.03	-0.25	0.08	-0.08		-0.13	0.04	-0.08	0.09	-0.14	-0.25
Common Stock	0.62	0.44	0.67	0.62	0.54	0.79	-0.62	0.2	-0.83	0.68	0.04	0.41	0.62	0.59	0.94	-0.25	0.88	-0.18	0.61	-0.13		0.72	0.64	-0.78	-0.01	0.79
Other Stockholder Equity	0.79	0.39	0.74	0.74	0.78	0.64	-0.74	0.13	-0.94	0.66	0.02	0.4	0.15	0.77	0.67	-0.45	0.64	-0.35	0.8	0.04	0.72		0.83	-0.3	0.22	0.66
Short Term Investments	0.88	0.28	0.59	0.53	0.81	0.45	-0.64	0.11	-0.74	0.55	0.01	0.34	0.06	0.91	0.54	-0.36	0.63	-0.29	0.92	-0.08	0.64	0.83		-0.22	0.08	0.47
Short Long Term Debt	-0.18	-0.17	-0.26	-0.26	-0.11	-0.59	0.42	-0.26	0.55	-0.31	0.09	-0.15	-0.84	-0.15	-0.81	0.04	-0.84	0.03	-0.17	0.09	-0.78	-0.3	-0.22		0.12	-0.48
Net Receivables	0.15	0.18	0.46	0.31	0.11	0.4	-0.24	0.14	-0.19	0.27	-0.09	0.26	-0.15	0.04	0.08	-0.04	-0.05	0.0	0.11	-0.14	-0.01	0.22	0.08	0.12		0.41
Capital Lease Obligations	0.49	0.43	0.91	0.71	0.36	0.97	-0.64	0.27	-0.74	0.7	-0.08	0.5	0.43	0.39	0.86	-0.1	0.58	-0.02	0.45	-0.25	0.79	0.66	0.47	-0.48	0.41

Click cells to compare fundamentals

ATyr Pharma, Account Relationship Matchups

ATyr Pharma, fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	38.7M	115.5M	95.8M	120.7M	96.8M	78.2M
Short Long Term Debt Total	2.2M	1.4M	11.5M	15.1M	13.3M	10.8M
Other Current Liab	3.6M	4.0M	9.9M	11.6M	9.4M	5.6M
Total Current Liabilities	5.9M	6.0M	13.9M	16.4M	15.0M	11.1M
Total Stockholder Equity	31.7M	109.3M	71.5M	90.7M	70.0M	43.1M
Property Plant And Equipment Net	3.0M	1.8M	11.6M	14.0M	11.9M	12.5M
Net Debt	(14.7M)	(958K)	1.6M	(7.4M)	2.2M	2.3M
Retained Earnings	(338.5M)	(372.3M)	(417.6M)	(468.0M)	(532.0M)	(505.4M)
Accounts Payable	1.4M	1.0M	3.1M	3.5M	4.3M	2.3M
Cash	17.0M	2.3M	10.0M	22.5M	11.1M	16.1M
Non Current Assets Total	3.2M	2.0M	14.9M	17.7M	14.9M	9.2M
Non Currrent Assets Other	213K	158K	193K	131K	3.0M	3.2M
Cash And Short Term Investments	31.7M	107.9M	66.1M	98.2M	72.1M	64.8M
Common Stock Shares Outstanding	9.2M	19.1M	28.4M	53.6M	74.3M	78.0M
Liabilities And Stockholders Equity	38.7M	115.5M	95.8M	120.7M	96.8M	78.2M
Non Current Liabilities Total	1.4M	398.0K	10.6M	13.8M	12.0M	17.4M
Other Current Assets	1.8M	5.2M	3.0M	2.4M	8.1M	8.5M
Total Liab	7.2M	6.4M	24.5M	30.2M	27.0M	25.4M
Total Current Assets	35.5M	113.6M	80.9M	103.0M	82.0M	69.0M
Short Term Debt	861K	980K	894K	1.3M	1.3M	2.3M
Common Stock	11K	28K	29K	63K	84K	88.2K
Other Stockholder Equity	370.2M	481.8M	489.5M	558.7M	602.0M	375.4M
Accumulated Other Comprehensive Income	(40K)	(43K)	(263K)	(433K)	(74K)	(42K)
Short Term Investments	14.7M	105.6M	56.2M	75.6M	61.1M	50.4M

Pair Trading with ATyr Pharma,

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ATyr Pharma, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ATyr Pharma, will appreciate offsetting losses from the drop in the long position's value.

Moving together with ATyr Stock

0.76	VKTX	Viking Therapeutics	Pair Corr
0.69	ELEV	Elevation Oncology	Pair Corr
0.61	XFOR	X4 Pharmaceuticals	Pair Corr

The ability to find closely correlated positions to ATyr Pharma, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ATyr Pharma, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ATyr Pharma, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling aTyr Pharma, to buy it.

The correlation of ATyr Pharma, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ATyr Pharma, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if aTyr Pharma, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for ATyr Pharma, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for ATyr Stock Analysis

When running ATyr Pharma,'s price analysis, check to measure ATyr Pharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ATyr Pharma, is operating at the current time. Most of ATyr Pharma,'s value examination focuses on studying past and present price action to predict the probability of ATyr Pharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ATyr Pharma,'s price. Additionally, you may evaluate how the addition of ATyr Pharma, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC